Palatin Technologies, Inc.
(NYSE Amex Equities : PTN)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Are you a Dividend Trader
Learn how to make passive income from the best dividend stocks.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
AMGNAmgen Inc.
0.76%195.471.3%$555.99m
GILDGilead Sciences, Inc.
0.24%66.520.9%$368.70m
ALXNAlexion Pharmaceuticals, Inc.
-0.79%107.402.0%$321.44m
ILMNIllumina, Inc.
1.14%300.913.5%$301.00m
BIIBBiogen Inc.
1.86%236.631.3%$288.49m
CELGCelgene Corporation
-0.23%98.401.3%$282.90m
AAgilent Technologies, Inc.
0.43%77.901.6%$193.04m
SRPTSarepta Therapeutics, Inc.
-2.25%86.0014.7%$180.31m
VRTXVertex Pharmaceuticals Incorporated
1.44%174.941.9%$173.66m
REGNRegeneron Pharmaceuticals, Inc.
-0.90%281.622.6%$171.53m
EXASExact Sciences Corporation
-1.82%106.7124.1%$132.03m
ACADACADIA Pharmaceuticals Inc.
3.35%40.4513.9%$98.63m
INCYIncyte Corporation
0.47%76.432.5%$83.43m
BMRNBioMarin Pharmaceutical Inc.
-0.21%72.654.3%$76.16m
IONSIonis Pharmaceuticals, Inc.
-1.02%66.208.2%$63.42m

Company Profile

Palatin Technologies, Inc. is a biopharmaceutical company, which engages in the development of medicines based on molecules that modulate the activity of the melanocortin and natriuretic peptide receptor systems. Its primary product candidate is marketed under the Vyleesi brand, the trade name for bremelanotide, a peptide melanocortin receptor 4 agonist for the treatment of premenopausal women with acquired, generalized, hypoactive sexual desire disorder (HSDD). The company was founded by Carl Spana and John K. A. Prendergast on November 21, 1986 and is headquartered in Cranbury, NJ.